REFERENCES
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.https://doi.org/10.1056/NEJMoa2001017
2. World Health Organization. Coronavirus disease (COVID-2019) situation
reports-102 (1 May 2020). Accessed 15 January 2021.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the
coronavirus disease 2019 (COVID-19) outbreak in China : summary of a
report of 72314 cases from the Chinese center for disease control and
prevention. JAMA 2020.https://doi.org/10.1001/jama.2020.2648
4. Lang W, Wenbo H, Xiaomei Y, Dalong H, Mingwei B, et al. Coronavirus
Disease 2019 in elderly patients: characteristics and prognostic factors
based on 4-week follow-up, J Infection 2020 639–645.https://doi.org/10.1016/j.jinf.2020.03.019
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological
and clinical characteristics of 99 cases of 2019 novel coronavirus
pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb
15;395(10223):507-513.https://doi.org/10.1016/S0140-6736(20)30211-7
6. Santé Publique France. Point épidémiologique COVID-19 au 21 Mai 2020.
Accessed 15 January 2021.
7. Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and
meta-analysis of pharmacist-led fee-for-services medication review. Br J
Clin Pharmacol. 2013 Jan;77(1):102-15.https://doi.org/10.1111/bcp.12140
8. Freyer J, Hueter L, Kasprick L, Frese T, Sultzer R, Schiek S, et al.
Drug-related problems in geriatric rehabilitation patients after
discharge – A prevalence analysis and clinical case scenario-based
pilot study. Res Soc Adm Pharm. 2018;14(7):628–37. 21.https://doi.org/10.1016/j.sapharm.2017.07.009
9. Bedouch P, Allenet B, Labarere J, Brudieu E, Chen C, Chevrot D, et
al. Diffusion des opinions pharmaceutiques dans le cadre d’une activité
de pharmacie Clinique en unité de soins, Therapie, Volume 60, Issue 5,
2005, Pages 515-522.https://doi.org/10.2515/therapie:2005015
10. Gutiérrez-Valencia M, Izquierdo M, Beobide-Telleria I, et al.
Medicine optimization strategy in an acute geriatric unit: The
pharmacist in the geriatric team. Geriatr Gerontol Int.
2019;19(6):530-536.https://doi.org/10.1111/ggi.13659
11. Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related
problems in admitted geriatric patients: the impact of clinical
pharmacist interventions. BMC Geriatr. 2020;20(1):13. Published 2020 Jan
13.https://doi.org/10.1186/s12877-020-1413-7
12. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive
pharmacist intervention to reduce morbidity in patients 80 years or
older: a randomized controlled trial. Arch Intern Med.
2009;169(9):894-900. https://doi.org /10.1001/archinternmed.2009.71
13. Juste M. Recommandation de bonne pratique en pharmacie clinique.
Analyse d’ordonnance et niveaux d’analyse pharmaceutique. Pharm Hosp
Clin 2012;47:293–5.https://doi.org/10.1016/j.phclin.2012.10.082
14. Laroche ML, Bouthier F, Merle L, Charmes JP. Médicaments
potentiellement inappropriés aux personnes âgées : intérêt d’une liste
adaptée à la pratique médicale française. Rev Med Intern
2009;30:592–601.https://doi.org/10.1016/j.revmed.2008.08.010
15. Lang PO, Dramé M, Guignard B, et al. Les critères STOPP/START.v2 :
adaptation en langue française. NPG Neurol Psychiatr Geriatrie
2015;15:323–36.https://doi.org/10.1016/j.npg.2015.08.001
16. Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B,
et al. Validation of
an instrument for the documentation of clinical pharmacists’
interventions. Pharm World Sci. 2006
Aug;28(4):181-8.https://doi.org/10.1007/s11096-006-9027-5
17. Vo TH, Evaluation of the potential impact of pharmacist
interventions: development and validation of the CLEO multidimensional
tool- Université Grenoble-Alpes (2015).https://tel.archives-ouvertes.fr/tel-01315619
18. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community
pharmacists’ contribution during a public health crisis. Res Social Adm
Pharm. 2020 Mar 31:S1551-7411(20)30292-8.https://doi.org/10.1016/j.sapharm.2020.03.015
19. Li H, Zheng S, Liu F, Liu W, Zhao R. Fighting against COVID-19:
Innovative strategies for clinical pharmacists. Res Social Adm Pharm.
2020 Apr 6:S1551-7411(20)30328-4.https://doi.org/10.1016/j.sapharm.2020.04.003
20. Burgess LH, Cooper MK, Wiggins EH, Miller KM, Murray E, Harris S,
Kramer JS. Utilizing Pharmacists to Optimize Medication Management
Strategies During the COVID-19 Pandemic. J Pharm Pract. 2020 Oct
5:897190020961655.https://doi.org/10.1177/0897190020961655
21. Surapat B, Sungkanuparph S, Kirdlarp S, Lekpittaya N, Chunnguleum K.
Role of clinical pharmacists in telemonitoring for patients with
Coronavirus Disease 2019 (COVID-19). J Clin Pharm Ther. 2020 Oct 21.https://doi.org/10.1111/jcpt.13293
22. Collins CD, West N, Sudekum DM, Hecht JP. Perspectives from the
frontline: A pharmacy department’s response to the COVID-19 pandemic, AM
J Health-Syst PH, Volume 77, Issue 17, 1 September 2020, Pages
1409–1416.
https://doi.org/10.1093/ajhp/zxaa176
23. Perez M, Masse M, Deldicque A, et al. Analysis of clinical
pharmacist interventions in the COVID-19 units of a French university
hospital. Eur J Hosp Pharm. Published Online First: 11 March 2021.
https://doi.org/10.1136/ejhpharm-2020-002542
24. Raimbault-Chupin M, Spiesser-Robelet L, Guir V et al. Drug related
problems and pharmacist interventions in a geriatric unit employing
electronic prescribing. Int J Clin Pharm 35, 847–853 (2013).https://doi.org/10.1007/s11096-013-9821-9
25. Chatelet J-N, Thèse en vue du diplôme d’état de Pharmacie,
Evaluation de l’impact clinique de la présence pharmaceutique dans le
service de court séjour gériatrique au Centre Hospitalier d’Armentières.
Université de Lille 2, 2016.
26. Lewis PJ, Dornan, T, Taylor D et al. Prevalence, Incidence and
Nature of Prescribing Errors in Hospital Inpatients. Drug-Safety 2009,
32, 379–389.https://doi.org/10.2165/00002018-200932050-00002
27. Courtman B, Stallings S, Characterization of Drug-Related Problems
in Elderly Patients on Admission to a Medical Ward. Can J Hosp Pharm
1995; 48:161-166
https://doi.org/10.4212/cjhp.v48i3.2275
28. Castronovo A, Gervais F, Mongaret C, Slimano C, Pharmacists’
interventions on prescription problems in one French community pharmacy:
A prospective pilot study, Ann Pharm Fr 2018, 76 (4):299-305.
https://doi.org/10.1016/j.pharma.2018.02.002.
29. Gervais F, Novais T, Goutelle S, Chappuy M, Parat S, Cabelguenne D,
et al. Drug-related problems among older patients: Analysis of 8 years
of pharmacist’s interventions, Ann Pharm Fr 2021https://doi.org/10.1016/j.pharma.2021.02.002.
30. Paillet-Testart D, Melin N, Bourgoin F, Hocquette D, Dubois J.
Enquête achat et consommation des médicaments à l’hôpital : une enquête
à découvrir. Rev. épidémiol. santé publique
Volume
67, Supplement 2, March 2019, Page S93
31. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major
hemorrhage and tolerability of warfarin in the first year of therapy
among elderly patients with atrial fibrillation. Circulation. 2007 May
29;115(21):2689-96.https://doi.org/10.1161/circulationaha.106.653048
32. Jansen J, Naganathan V, Carter S M, McLachlan A
J, Nickel B, Irwig L et al. Too much medicine in older people?
Deprescribing through shared decision making BMJ 2016; 353 :i2893
https://doi.org/10.1136/bmj.i2893
33. Franck C, Erica Weir. Deprescribing for older patients. CMAJ Dec
2014, 186 (18) 1369-1376.https://dx.doi.org/10.1503%2Fcmaj.131873
34. Bertoliatti-Fontana G, Bertho M, Tiret I, Chenailler C, Varin R,
Doucet J. Efficacité des interventions pharmaceutiques : comparaison de
deux modalités d’analyses pharmaceutiques en médecine interne. Pharm
Hosp Clin 2020; 55: 48–55.https://doi.org/10.1016/j.phclin.2019.09.002
35. Reinau D, Furrer C, Stämpfli D, Bornand D, Meier CR. Evaluation of
drug-related problems and subsequent clinical pharmacists’ interventions
at a Swiss university hospital. J Clin Pharm Ther. 2019;44(6):924-931.
36. Mongaret C, Quillet P, Vo TH, et al. Predictive factors for
clinically significant pharmacist interventions at hospital
admission. Medicine (Baltimore). 2018;97(9):e9865.http://dx.doi.org/10.1097/MD.0000000000009865
37. Zamparutti P, Nicolle I, Polard E, Le Duff M. Analyse de
prescription : 2. Résultats obtenus dans un service de gériatrie. Pharm
Hosp Fr. 1997;(119):12-16.
38. Ziane A, Ngami C, Youb R, Hazem Atri M, Aikpa R, Kabirian F, et al.
Évaluation de la qualité des interventions pharmaceutiques chez le sujet
âgé de plus de 75 ans. J Pharm Clin-Series. 2013;32(4):243-249.https://doi.org/10.1684/jpc.2013.0261
39. Bedouch P, Allenet B, Labarere J, Brudieu E, Chen C, Chevrot D, et
al. Diffusion des opinions pharmaceutiques dans le cadre d’une activité
de pharmacie clinique en unité de soins. Therapie. 2005;60(5):515–22.https://doi.org/10.2515/therapie:2005015